KR102093495B1 - C형 간염 바이러스에 대한 키메라 백신 항원 - Google Patents

C형 간염 바이러스에 대한 키메라 백신 항원 Download PDF

Info

Publication number
KR102093495B1
KR102093495B1 KR1020157012656A KR20157012656A KR102093495B1 KR 102093495 B1 KR102093495 B1 KR 102093495B1 KR 1020157012656 A KR1020157012656 A KR 1020157012656A KR 20157012656 A KR20157012656 A KR 20157012656A KR 102093495 B1 KR102093495 B1 KR 102093495B1
Authority
KR
South Korea
Prior art keywords
antigen
hcv
val
amino acids
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157012656A
Other languages
English (en)
Korean (ko)
Other versions
KR20150079694A (ko
Inventor
산티아고 듀나스 카레라
다이렌 아구일라 노리에가
얄레나 아마도르 카니자르스
리즈 알바레즈-라존체르 폰스 데 레온
길리안 마르티네즈 도나토
소니아 곤잘레스 블란코
Original Assignee
센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 filed Critical 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아
Publication of KR20150079694A publication Critical patent/KR20150079694A/ko
Application granted granted Critical
Publication of KR102093495B1 publication Critical patent/KR102093495B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157012656A 2012-11-05 2013-10-28 C형 간염 바이러스에 대한 키메라 백신 항원 Expired - Fee Related KR102093495B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
CU2012-0153 2012-11-05
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (2)

Publication Number Publication Date
KR20150079694A KR20150079694A (ko) 2015-07-08
KR102093495B1 true KR102093495B1 (ko) 2020-03-26

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012656A Expired - Fee Related KR102093495B1 (ko) 2012-11-05 2013-10-28 C형 간염 바이러스에 대한 키메라 백신 항원

Country Status (15)

Country Link
US (1) US9676825B2 (enExample)
EP (1) EP2915544B1 (enExample)
JP (1) JP6259831B2 (enExample)
KR (1) KR102093495B1 (enExample)
CN (1) CN104837498B (enExample)
AR (1) AR093341A1 (enExample)
AU (1) AU2013339846B2 (enExample)
CA (1) CA2901346C (enExample)
CU (1) CU24112B1 (enExample)
ES (1) ES2644801T3 (enExample)
IN (1) IN2015DN03925A (enExample)
MX (1) MX358507B (enExample)
RU (1) RU2639504C2 (enExample)
WO (1) WO2014067498A1 (enExample)
ZA (1) ZA201503036B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4516312A3 (en) 2015-07-07 2025-04-30 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
CN109963587A (zh) * 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
WO2018200892A1 (en) 2017-04-27 2018-11-01 The Trustees Of The University Of Pennsylvania NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS
AU2019233861A1 (en) 2018-03-16 2020-10-01 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
US20110256098A1 (en) * 2008-09-19 2011-10-20 David Apelian Immunotherapy for chronic hepatitis c virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
WO2007081848A2 (en) * 2006-01-04 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
CN102016026B (zh) * 2008-04-25 2014-07-02 东丽株式会社 含有来自丙型肝炎病毒的嵌合基因的核酸
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
US20110256098A1 (en) * 2008-09-19 2011-10-20 David Apelian Immunotherapy for chronic hepatitis c virus infection

Also Published As

Publication number Publication date
RU2015121429A (ru) 2016-12-27
CU20120153A7 (es) 2014-06-27
MX2015005651A (es) 2015-08-20
CA2901346C (en) 2019-04-23
ZA201503036B (en) 2016-01-27
CA2901346A1 (en) 2014-05-08
RU2639504C2 (ru) 2017-12-21
ES2644801T3 (es) 2017-11-30
AU2013339846A1 (en) 2015-05-14
EP2915544A1 (en) 2015-09-09
JP6259831B2 (ja) 2018-01-10
AR093341A1 (es) 2015-06-03
CN104837498B (zh) 2018-05-18
US9676825B2 (en) 2017-06-13
WO2014067498A1 (es) 2014-05-08
AU2013339846B2 (en) 2017-08-17
JP2015536936A (ja) 2015-12-24
US20150307558A1 (en) 2015-10-29
CU24112B1 (es) 2015-08-27
CN104837498A (zh) 2015-08-12
EP2915544B1 (en) 2017-08-09
KR20150079694A (ko) 2015-07-08
MX358507B (es) 2018-08-22
IN2015DN03925A (enExample) 2015-10-02

Similar Documents

Publication Publication Date Title
CA2462455C (en) Development of a preventive vaccine for filovirus infection in primates
KR102319845B1 (ko) 조류 숙주 세포에 대한 crispr-cas 시스템
KR20180048743A (ko) 2a 펩타이드를 포함하는 재조합 벡터
CN114126645B (zh) 冠状病毒刺突蛋白的修饰的s1亚基
KR20220016485A (ko) 미엘린 단백질 제로 프로모터를 갖는 aav 벡터, 및 샤르코-마리-투스 질환과 같은 슈반 세포-관련 질환을 치료하기 위한 이의 용도
AU2018281889B2 (en) Recombinant measles virus expressing Zika virus proteins and their applications
US12421524B2 (en) Expression vectors for eukaryotic expression systems
KR20230054840A (ko) rAAV 비리온의 유도 생산을 위한 안정화된 세포주
CN115968300A (zh) 用于体内转导的载体和方法
KR102093495B1 (ko) C형 간염 바이러스에 대한 키메라 백신 항원
AU2017233862B2 (en) Methods and compositions for increased double stranded RNA production
CN110225765B (zh) 减毒猪流感疫苗以及其制备和使用方法
DK2935601T3 (en) RECOMBINANT MICROBELL CELLS PRODUCING AT LEAST 28% EICOSAPENTAIC ACID AS DRY WEIGHT
KR102346159B1 (ko) 고효율 발현 벡터 및 이의 용도
AU753907B2 (en) Trans-somatics with gene transfer into mammary epithelial cells
KR20150100606A (ko) 아테리바이러스 단백질 및 발현 메커니즘
CN113025718A (zh) 调节eif4a3表达以调控肝癌细胞增殖能力的应用
CN113130009A (zh) 调节eif4a3表达以调控肝癌细胞凋亡、迁移和侵袭能力的应用
KR20240023100A (ko) 유전자 발현을 조절하기 위한 조성물 및 방법
KR102794718B1 (ko) 하이브리드 신호서열을 포함하는 재조합 벡터 및 이를 이용한 인간 인슐린 유사 성장인자-1의 분비 생산방법
EA049449B1 (ru) Модифицированная субъединица s1 шиповидного белка коронавируса
KR101590174B1 (ko) 세포 생존능 측정용 ｃｂａ-프로모터 리포터 벡터 및 그에 의해 형질감염된 세포주
HK40061400A (en) Recombinant vectors comprising genes for binding domains and secretable peptides
CN113677800A (zh) 包含用于结合结构域和可分泌肽的基因的重组载体
CN117500931A (zh) 麻疹-hiv或麻疹-htlv疫苗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230320